OR WAIT null SECS
Radiant Research/CRA has completed enrollment for the Dynavax Technologies Phase III clinical trial
Radiant Research/Clinical Research Advantage (Radiant/CRA), a wholly owned clinical trial site management organization, has completed enrollment for the Dynavax Technologies Phase III clinical trial of HEPLISAV-B™, an investigational adult hepatitis B vaccine. Radiant/CRA was awarded 100 percent of the study and 40 of its sites are conducting the trial, which has randomized over 8,250 adults, including over 1,100 diabetic subjects. The sites completed the enrollment three months ahead of schedule without the use of an outside recruiting company.
Read the full release here.